Table 4 SNCG expression in response to chemotherapy. Comparisons between patients with platinum-refractory (defined as disease progression with first-line chemotherapy) and patients with no evidence of disease (NED) or platinum-sensitive disease status (defined as disease recurrence within 6 months of first-line chemotherapy) and platinum-resistant are shown 

From: Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease